Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors

(2021) Sally CM. Lau et al.   Clinical Lung Cancer

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations

(2021) Shuo Yang et al.   Translational Lung Cancer Research

Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non–small cell lung cancer

(2021) Yasuto Yoneshima et al.   Journal of Thoracic Oncology

Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations

(2021) Felix C. Saalfeld et al.   Journal of Thoracic Oncology

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

(2021) Alex Friedlaender et al.   Nature Reviews Clinical Oncology

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

(2020) Florian Guisier et al.   Journal of Thoracic Oncology

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

(2020) Fei Xu et al.   Thoracic Cancer

Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy.

(2020) Guo-Chun Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions

(2020) Kaiyan Chen et al.   Thoracic Cancer

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

(2019) T Bachelot et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

(2019) Jean-Bernard Auliac et al.   ADVANCES IN THERAPY

Progress in research on paclitaxel and tumor immunotherapy

(2019) Linyan Zhu et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma

(2019) Wenfeng Fang et al.   ONCOLOGIST

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

(2018) Yan Wang et al.   BMC CANCER

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

(2018) Masayuki Takeda et al.   Oncotarget

PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.

(2018) Wei-Chu Victoria Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301

(2016) Shinya Sakata et al.   LUNG CANCER

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers

(2016) Juliana Eng et al.   LUNG CANCER

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY